Patents Assigned to Haro Pharmaceuticals Inc.
  • 18-20 member bi-polycyclic compounds
    Patent number: 10954194
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 23, 2021
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • 18-20 member bi-polycyclic compounds
    Patent number: 10752591
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 25, 2020
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • 18-20 member bi-polycyclic compounds
    Patent number: 10377715
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 13, 2019
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing